FDA adcomm votes against Lexicon type 1 diabetes and CKD drug

For the second time in five years, an FDA advisory committee voted against endorsing the benefit-risk profile of Lexicon's drug sotagliflozin. The Endocrinologic and Metabolic Drugs Advisory Committee voted 11-3 against the drug, an SGLT2 ...